Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin

References

• Norton L, Massagué J. Is cancer a disease of self-seeding?. Nat Med 2006; 12:875 - 8; http://dx.doi.org/10.1038/nm0806-875; PMID: 16892025
   PubMed Web of Science ®Google Scholar
• Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7:139 - 47; http://dx.doi.org/10.1038/nrc2067; PMID: 17218951
   PubMed Web of Science ®Google Scholar
• Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 2011; 81:1183 - 91; http://dx.doi.org/10.1016/j.bcp.2011.02.016; PMID: 21382350
   PubMed Web of Science ®Google Scholar
• Said SS, Pickering JG, Mequanint K. Advances in growth factor delivery for therapeutic angiogenesis. J Vasc Res 2013; 50:35 - 51; http://dx.doi.org/10.1159/000345108; PMID: 23154615
   PubMed Web of Science ®Google Scholar
• Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 2012; 9:498 - 509; http://dx.doi.org/10.1038/nrclinonc.2012.120; PMID: 22850752
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?. Cancer Biol Ther 2012; 13:247 - 63; http://dx.doi.org/10.4161/cbt.19594; PMID: 22481432
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492 - 507; http://dx.doi.org/10.1056/NEJMra0708126; PMID: 18669428
   PubMed Web of Science ®Google Scholar
• Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010; 128:1 - 36; http://dx.doi.org/10.1016/j.pharmthera.2010.04.015; PMID: 20546782
   PubMed Web of Science ®Google Scholar
• Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. Pharmacol Ther 2013; 139:341 - 58; http://dx.doi.org/10.1016/j.pharmthera.2013.05.003; PMID: 23694764
   PubMed Web of Science ®Google Scholar
• Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005; 15:297 - 310; http://dx.doi.org/10.1111/j.1750-3639.2005.tb00115.x; PMID: 16389942
   PubMed Web of Science ®Google Scholar
• Lakka SS, Rao JS. Antiangiogenic therapy in brain tumors. Expert Rev Neurother 2008; 8:1457 - 73; http://dx.doi.org/10.1586/14737175.8.10.1457; PMID: 18928341
   PubMedGoogle Scholar
• Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2012; 60:502 - 14; http://dx.doi.org/10.1002/glia.21264; PMID: 22379614
   PubMed Web of Science ®Google Scholar
• Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610 - 22; http://dx.doi.org/10.1038/nrn2175; PMID: 17643088
   PubMed Web of Science ®Google Scholar
• Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat Res 2004; 117:249 - 62; http://dx.doi.org/10.1007/978-1-4419-8871-3_15; PMID: 15015564
   PubMedGoogle Scholar
• Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011; 28:13 - 24; http://dx.doi.org/10.1007/s10014-010-0007-z; PMID: 21221826
   PubMed Web of Science ®Google Scholar
• Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 2012; 124:763 - 75; http://dx.doi.org/10.1007/s00401-012-1066-5; PMID: 23143192
   PubMed Web of Science ®Google Scholar
• Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 2009; 14:621 - 36; http://dx.doi.org/10.1634/theoncologist.2008-0272; PMID: 19487335
   PubMed Web of Science ®Google Scholar
• Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol 2008; 21:736 - 44; http://dx.doi.org/10.1097/WCO.0b013e3283131370; PMID: 19060566
   PubMed Web of Science ®Google Scholar
• Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009; 110:173 - 80; http://dx.doi.org/10.3171/2008.4.17492; PMID: 18834263
   PubMed Web of Science ®Google Scholar
• Takano S, Yamashita T, Ohneda O. Molecular therapeutic targets for glioma angiogenesis. J Oncol 2010; 2010:351908; http://dx.doi.org/10.1155/2010/351908; PMID: 20414463
   PubMedGoogle Scholar
• Khasraw M, Simeonovic M, Grommes C. Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther 2012; 12:1101 - 11; http://dx.doi.org/10.1517/14712598.2012.694422; PMID: 22663137
   PubMed Web of Science ®Google Scholar
• Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Y, Yamada Y, Marunaka T. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 1988; 41:1575 - 9; http://dx.doi.org/10.7164/antibiotics.41.1575; PMID: 3198491
   PubMed Web of Science ®Google Scholar
• Chen J, Ouyang ZG, Zhang SH, Zhen YS. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncol Rep 2007; 17:1445 - 51; PMID: 17487403
   PubMed Web of Science ®Google Scholar
• Zhen H, Xue Y, Zhen Y. [Inhibition of angiogenesis by antitumor antibiotic C1027 and its effect on tumor metastasis]. Zhonghua Yi Xue Za Zhi 1997; 77:657 - 60; PMID: 9772532
   PubMedGoogle Scholar
• Zhen YS, Ming XY, Yu B, Otani T, Saito H, Yamada Y. A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo) 1989; 42:1294 - 8; http://dx.doi.org/10.7164/antibiotics.42.1294; PMID: 2759910
   PubMed Web of Science ®Google Scholar
• Liu YP, Li QS, Huang YR, Zhou MJ, Liu CX. Pharmacokinetics of C-1027 in mice as determined by TCA-RA method. World J Gastroenterol 2005; 11:717 - 20; PMID: 15655829
   PubMed Web of Science ®Google Scholar
• Ru Q, Shang BY, Miao QF, Li L, Wu SY, Gao RJ, Zhen YS. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity. Eur J Pharm Sci 2012; 47:781 - 9; http://dx.doi.org/10.1016/j.ejps.2012.09.002; PMID: 22982402
   PubMed Web of Science ®Google Scholar
• Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C, Durando X. Temozolomide and unusual indications: review of literature. Cancer Treat Rev 2013; 39:125 - 35; http://dx.doi.org/10.1016/j.ctrv.2012.06.002; PMID: 22818211
   PubMed Web of Science ®Google Scholar
• Grossman R, Tyler B, Hwang L, Zadnik P, Lal B, Javaherian K, Brem H. Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. J Neurosurg 2011; 115:1139 - 46; http://dx.doi.org/10.3171/2011.8.JNS11125; PMID: 21923243
   PubMed Web of Science ®Google Scholar
• Zhang YH, Yue ZJ, Zhang H, Tang GS, Wang Y, Liu JM. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. Eur J Pharm Biopharm 2010; 76:371 - 5; http://dx.doi.org/10.1016/j.ejpb.2010.08.011; PMID: 20816959
   PubMed Web of Science ®Google Scholar
• Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, van Furth WR, Richel DJ. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 2010; 21:1723 - 7; http://dx.doi.org/10.1093/annonc/mdp591; PMID: 20064829
   PubMed Web of Science ®Google Scholar
• Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol 2012; 181:1126 - 41; http://dx.doi.org/10.1016/j.ajpath.2012.06.030; PMID: 22858156
   PubMed Web of Science ®Google Scholar
• Kennedy DR, Gawron LS, Ju J, Liu W, Shen B, Beerman TA. Single chemical modifications of the C-1027 enediyne core, a radiomimetic antitumor drug, affect both drug potency and the role of ataxia-telangiectasia mutated in cellular responses to DNA double-strand breaks. Cancer Res 2007; 67:773 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-06-2893; PMID: 17234789
   PubMed Web of Science ®Google Scholar
• Kennedy DR, Ju J, Shen B, Beerman TA. Designer enediynes generate DNA breaks, interstrand cross-links, or both, with concomitant changes in the regulation of DNA damage responses. Proc Natl Acad Sci U S A 2007; 104:17632 - 7; http://dx.doi.org/10.1073/pnas.0708274104; PMID: 17978180
   PubMed Web of Science ®Google Scholar
• Liu W, Christenson SD, Standage S, Shen B. Biosynthesis of the enediyne antitumor antibiotic C-1027. Science 2002; 297:1170 - 3; http://dx.doi.org/10.1126/science.1072110; PMID: 12183628
   PubMed Web of Science ®Google Scholar
• Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O’Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007; 9:354 - 63; http://dx.doi.org/10.1215/15228517-2007-006; PMID: 17452651
   PubMed Web of Science ®Google Scholar
• Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 2006; 16:33 - 9; PMID: 16786120
   PubMed Web of Science ®Google Scholar
• Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77:1156 - 64; http://dx.doi.org/10.1212/WNL.0b013e31822f02e1; PMID: 21880994
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29:142 - 8; http://dx.doi.org/10.1200/JCO.2010.30.2729; PMID: 21135282
   PubMed Web of Science ®Google Scholar
• Sandström M, Johansson M, Bergström P, Bergenheim AT, Henriksson R. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 2008; 88:1 - 9; http://dx.doi.org/10.1007/s11060-008-9527-3; PMID: 18228115
   PubMed Web of Science ®Google Scholar
• Cantarella G, Risuglia N, Dell’eva R, Lempereur L, Albini A, Pennisi G, Scoto GM, Noonan DN, Bernardini R. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer 2006; 94:1428 - 35; http://dx.doi.org/10.1038/sj.bjc.6603092; PMID: 16622457
   PubMed Web of Science ®Google Scholar
• Paku S. Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 1998; 4:62 - 75; http://dx.doi.org/10.1007/BF02904699; PMID: 9555124
   PubMedGoogle Scholar
• Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24:203 - 18; PMID: 9129690
   PubMed Web of Science ®Google Scholar
• Munaut C, Noël A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003; 106:848 - 55; http://dx.doi.org/10.1002/ijc.11313; PMID: 12918061
   PubMed Web of Science ®Google Scholar
• Kurzen H, Schmitt S, Näher H, Möhler T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 2003; 14:515 - 22; http://dx.doi.org/10.1097/00001813-200308000-00003; PMID: 12960735
   PubMed Web of Science ®Google Scholar
• Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, Lefranc F. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 2008; 10:1383 - 92; PMID: 19048117
   PubMed Web of Science ®Google Scholar
• Wu Z, Hofman FM, Zlokovic BV. A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J Neurosci Methods 2003; 130:53 - 63; http://dx.doi.org/10.1016/S0165-0270(03)00206-1; PMID: 14583404
   PubMed Web of Science ®Google Scholar
• Yousif S, Marie-Claire C, Roux F, Scherrmann JM, Declèves X. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 2007; 1134:1 - 11; http://dx.doi.org/10.1016/j.brainres.2006.11.089; PMID: 17196184
   PubMed Web of Science ®Google Scholar
• Wang J, Yao L, Zhao S, Zhang X, Yin J, Zhang Y, Chen X, Gao M, Ling EA, Hao A, et al. Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells. Cancer Biol Ther 2012; 13:389 - 400; http://dx.doi.org/10.4161/cbt.19237; PMID: 22313638
   PubMed Web of Science ®Google Scholar
• Ali MA, Choy H, Habib AA, Saha D. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 2007; 9:370 - 81; http://dx.doi.org/10.1593/neo.07136; PMID: 17534442
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 2004; 10:5622 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-04-0308; PMID: 15328205
   PubMed Web of Science ®Google Scholar
• Rosca EV, Koskimaki JE, Pandey NB, Wolff AC, Popel AS. Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther 2011; 12:808 - 17; http://dx.doi.org/10.4161/cbt.12.9.17677; PMID: 21878750
   PubMed Web of Science ®Google Scholar
• Zhang W, Lu Y, Xu B, Wu J, Zhang L, Gao M, Zheng S, Wang A, Zhang C, Chen L, et al. Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vitro. Cancer Biol Ther 2009; 8:1489 - 99; http://dx.doi.org/10.4161/cbt.8.15.8948; PMID: 19483477
   PubMed Web of Science ®Google Scholar
• Gu JW, Young E, Patterson SG, Makey KL, Wells J, Huang M, Tucker KB, Miele L. Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice. Cancer Biol Ther 2011; 11:910 - 7; http://dx.doi.org/10.4161/cbt.11.10.15473; PMID: 21451264
   PubMed Web of Science ®Google Scholar
• Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, Thor RK, Damoiseaux R, Liang C, Huang J. Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther 2012; 11:1320 - 31; http://dx.doi.org/10.1158/1535-7163.MCT-11-0954; PMID: 22491797
   PubMed Web of Science ®Google Scholar
• Gong JH, Liu XJ, Li Y, Zhen YS. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemother Pharmacol 2012; 69:1323 - 32; http://dx.doi.org/10.1007/s00280-012-1827-9; PMID: 22311160
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M, Hirakawa K. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009; 100:2402 - 10; http://dx.doi.org/10.1111/j.1349-7006.2009.01315.x; PMID: 19764996
   PubMed Web of Science ®Google Scholar